Last update 21 Nov 2024

Fepradinol

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Fepradinol (INN), Dalgen

+ [1]

Target-

Mechanism-

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

InflammationPain

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure

Molecular FormulaC12H19NO2

InChIKeyPVOOBRUZWPQOER-UHFFFAOYSA-N

CAS Registry36981-91-6

100 Clinical Results associated with Fepradinol

100 Translational Medicine associated with Fepradinol

100 Patents (Medical) associated with Fepradinol

Literatures (Medical) associated with Fepradinol

01 Jan 2004·American Journal of Clinical DermatologyQ2 · MEDICINE

Sympathomimetic Drug Allergy

Q2 · MEDICINE

Article

Author: Teresa Herrero ; Pilar Tornero ; Vāctor Matheu ; Ruth Barranco ; Manuel de Barrio ; Consolación de Frutos ; Mā J. Trujillo ; Angel Rodríguez

INTRODUCTIONSympathomimetic (alpha-adrenergic) drugs are mainly used because of their vasoconstrictor properties, for nasal congestion, or as mydriatics. Although sympathomimetic drugs are used often, allergic reactions are rare, especially when the drugs are administered systemically. Cross-reactivity may exist among catecholamine derivatives, although reported data on this are contradictory. In this study, we investigate if there is cross-reactivity in patch tests among these drugs.MATERIAL AND METHODSPatch tests with 10% phenylephrine and 10% pseudoephedrine in petrolatum, and 10% and 20% ephedrine, 10% phenylpropanolamine, 5% fepradinol, 1% methoxamine, and 10% oxymetazoline, all administered in dimethyl sulfoxide (DMSO), were carried out in 14 patients with a history of allergy to any of these drugs. DMSO was used as the negative control.RESULTSAll patients except one (patient number five) showed positive patch-test reactions to at least two different drugs. Nine patients (64.3%) were cross-sensitized to three or more different drugs, and 57.1% of patients were sensitized to four or more sympathomimetic drugs. Patients who experienced generalized rashes caused by orally administered pseudoephedrine had a stronger response and more cross-reactivity with other sympathomimetic drugs in patch tests than those who experienced local contact dermatitis.CONCLUSIONSWe conclude that there is cross-reactivity among the different sympathomimetic drugs tested, especially if the drug is administered systemically.

01 Mar 1997·Contact DermatitisQ2 · MEDICINE

No evidence of cross‐reaction between fepradinol and other phenylethanolamines

Q2 · MEDICINE

Article

Author: R. Ilardia ; R. Soloeta ; M. Gonzælez‐Güemes ; J. J. Goday ; J. M. Oleaga ; I. Yanguas

01 Jan 1996·DermatologyQ4 · MEDICINE

Multiple Cutaneous Sensitization to Nonsteroidal Anti-Inflammatory Drugs

Q4 · MEDICINE

Article

Author: Revenga, F ; Gonzalo, M A

The use of topical nonsteroidal anti-inflammatory drugs is widespread (particularly in countries bordering the Mediterranean). Compared to their wide use, the incidence of published adverse cutaneous effects appears minimal, although they are increasing. Most of them are a form of allergic contact dermatitis (ACD). Multiple sensitization and/or cross-reactions are rarely reported. Interestingly, our patient presented ACD with diclofenac and etofenamate (both from different chemical groups) and, furthermore, patch tests were positive with bencydamine and indomethacin (both indolacetic acid derivatives), piroxicam and fepradinol. We think that our results could not be explained due to cross-reactivity, and that multiple sensitization was more likely.

100 Deals associated with Fepradinol

External Link

KEGG	Wiki	ATC	Drug Bank
D07954	-	V03	DB15902

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Inflammation	-	-	-
Pain	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis